Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107213
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bento, Dulce | - |
dc.contributor.author | Jesus, Sandra | - |
dc.contributor.author | Lebre, Filipa | - |
dc.contributor.author | Gonçalves, Teresa | - |
dc.contributor.author | Borges, Olga | - |
dc.date.accessioned | 2023-06-15T08:31:05Z | - |
dc.date.available | 2023-06-15T08:31:05Z | - |
dc.date.issued | 2019-02-09 | - |
dc.identifier.issn | 1999-4923 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/107213 | - |
dc.description.abstract | Current vaccine research is mostly based on subunit antigens. Despite the better toxicity profile of these antigens they are often poorly immunogenic, so adjuvant association has been explored as a strategy to obtain a potent vaccine formulation. Recently, mast cell activators were recognized as a new class of vaccine adjuvants capable of potentiating mucosal and systemic immune responses. In this study, a co-adjuvanted delivery system was developed and characterized, combining the mast cell activator C48/80 with chitosan nanoparticles (Chi-C48/80 NPs), and the results were compared with plain chitosan nanoparticles. The adsorption of model antigens onto the NP surface as well as the biocompatibility of the system was not affected by the incorporation of C48/80 in the formulation. The stability of the nanoparticles was demonstrated by studying the variation of size and zeta potential at different times, and the ability to be internalized by antigen presenting cells was confirmed by confocal microscopy. Vaccination studies with hepatitis B surface antigen loaded Chi-C48/80 NPs validated the adjuvanticity of the delivery system, demonstrating for the first time a successful association between a mast cell activator and chitosan nanoparticles as a vaccine adjuvant for hepatitis B virus, applied to a nasal vaccination strategy. | pt |
dc.description.sponsorship | This work was financed by the European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme, under project CENTRO-01-0145-FEDER-000008:BrainHealth 2020, and through the COMPETE 2020—Operational Programme for Competitiveness and Internationalisation. This work was also financed by Portuguese national funds via FCT (Foundation for Science and Technology), I.P., under strategic project POCI-01-0145-FEDER-007440 as well as projects POCI-01-0145-FEDER-030331 and ProSafe/0001/2016 and via FCT doctoral fellowship SFRH/BD/65141/2009. SEM analysis was performed in CEMUP (under REEQ/1062/CTM/2005 and REDE/1512/RME/2005 funding contracts from FCT) | pt |
dc.language.iso | eng | pt |
dc.publisher | MDPI | pt |
dc.relation | CENTRO-01-0145-FEDER-000008/BrainHealth2020 | pt |
dc.relation | PTDC/MEC-GAS/30331/2017 | pt |
dc.relation | SFRH/BD/65141/2009 | pt |
dc.relation | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID/NEU/04539/2013/PT | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | compound 48/80 | pt |
dc.subject | chitosan | pt |
dc.subject | nanoparticles | pt |
dc.subject | mast cell activator | pt |
dc.subject | vaccine adjuvant | pt |
dc.subject | nasal vaccination | pt |
dc.title | Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant | pt |
dc.type | article | - |
degois.publication.firstPage | 72 | pt |
degois.publication.issue | 2 | pt |
degois.publication.title | Pharmaceutics | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3390/pharmaceutics11020072 | pt |
degois.publication.volume | 11 | pt |
dc.date.embargo | 2019-02-09 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
crisitem.project.grantno | BrainHealth 2020: Deteção Precoce, Neuro-modulação e Terapias Avançadas para Neuropatologias | - |
crisitem.project.grantno | CNC. IBILI | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0001-9347-0535 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais I&D CNC - Artigos em Revistas Internacionais FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Chitosan-plus-compound-4880-Formulation-and-preliminary-evaluation-as-a-hepatitis-B-vaccine-adjuvantPharmaceutics.pdf | 4.11 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License